M&A / Deals Gan & Lee and JW Pharmaceutical agree on bofanglutide commercialisation Pharmaceutical Business ReviewBofanglutide is a bi-weekly glucagon-like peptide-1 receptor agonist (GLP-1RA) discovered and developed by Gan Lee.M&A / DealsMetabolic & GLP-1Read full story pharminent April 10, 2026 (Last updated: April 10, 2026) Pharmaceutical Business Review Bofanglutide is a bi-weekly glucagon-like peptide-1 receptor agonist (GLP-1RA) discovered and developed by Gan Lee. M&A / DealsMetabolic & GLP-1Read full story Post navigation Previous: Precision Medicine in Early Oncology Trials: Biomarkers as Strategic DriversNext: Roche and C4 Therapeutics to advance degrader-antibody conjugates research Related Stories M&A / Deals Assertio accepts new buyout bid; AI biotech Isomorphic banks $2B pharminent May 13, 2026 M&A / Deals BMS, Hengrui build 13-asset pipeline in $15B+ onco-immune deal pharminent May 12, 2026 M&A / Deals Cellular Intelligence scoops up Novo’s Parkinson’s therapy pharminent May 12, 2026
